Evidence map›Paper›PMID 33590417›Full record

ArticleHealth care management science2021

From predictions to prescriptions: A data-driven response to COVID-19.

Dimitris Bertsimas, Leonard Boussioux, Ryan Cory-Wright, Arthur Delarue, Vassilis Digalakis, Alexandre Jacquillat, Driss Lahlou Kitane, Galit Lukin, Michael Li, Luca Mingardi and 11 more

Abstract read
In one paragraph

Article in Health care management science, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Evaluating infectious disease forecasts with allocation scoring rules.Journal of the Royal Statistical Society. Series A, (Statistics in Society) · 2024
    Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Dimitris BertsimasSloan School of Management, Massachusetts Institute of Technology, Cambridge, MA 02142, USA. dbertsim@mit.edu.ORCID http://orcid.org/0000-0002-1985-1003
Leonard BoussiouxOperations Research Center, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
Ryan Cory-WrightOperations Research Center, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
Arthur DelarueOperations Research Center, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
Vassilis DigalakisOperations Research Center, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
Alexandre JacquillatSloan School of Management, Massachusetts Institute of Technology, Cambridge, MA 02142, USA.
Driss Lahlou KitaneOperations Research Center, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
Galit LukinOperations Research Center, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
Michael LiOperations Research Center, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
Luca MingardiOperations Research Center, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
Omid NohadaniBenefits Science Technologies, Boston, MA 02110, USA.
Agni OrfanoudakiOperations Research Center, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
Theodore PapalexopoulosOperations Research Center, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
Ivan PaskovOperations Research Center, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
Jean PauphiletLondon Business School, London, NW1 4SA, UK.
Omar Skali LamiOperations Research Center, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
Bartolomeo StellatoOperations Research and Financial EngineeringPrinceton University, Princeton, NJ, 08544, USA.
Hamza Tazi BouardiOperations Research Center, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
Kimberly Villalobos CarballoOperations Research Center, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
Holly WibergOperations Research Center, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
Cynthia ZengOperations Research Center, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.

Funding

National Science Foundation #174530
6 · The paper itself

Abstract

The COVID-19 pandemic has created unprecedented challenges worldwide. Strained healthcare providers make difficult decisions on patient triage, treatment and care management on a daily basis. Policy makers have imposed social distancing measures to slow the disease, at a steep economic price. We design analytical tools to support these decisions and combat the pandemic. Specifically, we propose a comprehensive data-driven approach to understand the clinical characteristics of COVID-19, predict its mortality, forecast its evolution, and ultimately alleviate its impact. By leveraging cohort-level clinical data, patient-level hospital data, and census-level epidemiological data, we develop an integrated four-step approach, combining descriptive, predictive and prescriptive analytics. First, we aggregate hundreds of clinical studies into the most comprehensive database on COVID-19 to paint a new macroscopic picture of the disease. Second, we build personalized calculators to predict the risk of infection and mortality as a function of demographics, symptoms, comorbidities, and lab values. Third, we develop a novel epidemiological model to project the pandemic's spread and inform social distancing policies. Fourth, we propose an optimization model to re-allocate ventilators and alleviate shortages. Our results have been used at the clinical level by several hospitals to triage patients, guide care management, plan ICU capacity, and re-distribute ventilators. At the policy level, they are currently supporting safe back-to-work policies at a major institution and vaccine trial location planning at Janssen Pharmaceuticals, and have been integrated into the US Center for Disease Control's pandemic forecast.

Indexed as

COVID-19COVID-19 Drug TreatmentMachine LearningAgedDatabases, FactualFemaleForecastingHumansIntensive Care UnitsMaleMiddle AgedModels, StatisticalPandemicsPolicy MakingPrognosisRisk AssessmentCOVID-19Epidemiological modelingMachine learningOptimization

Identifiers

PMID33590417
PMCPMC7883965

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.